Th2 targeting therapy prevents the development of asthma and AD, as it is aimed at shared for the atopic march immunological components such as IL -13, IL- 4, TSLP etc. For many years the treatment of AD consisted in the use of emollients, phototherapy, caucineurin inhibitors, corticosteroids and other immunosuppressive therapies. Here, TSLP is linked to Alzheimer disease.